Fortrea (FTRE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting called to order at 8:00 A.M. Eastern Time on June 9, 2026, with board members and Deloitte & Touche present.
Rules of conduct and meeting format outlined, including proposal introductions and voting procedures.
Inspector of Election and secretary roles introduced and confirmed.
Corporate governance
Notice of meeting, proxy materials, and stockholder list confirmed and filed for inspection.
Quorum established with 86,193,770 shares represented, exceeding the majority required.
Board and executive committee updates
Three Class III director nominees presented: Peter M. Neupert, Anshul Thakral, and William J. Sharbaugh.
No additional nominations received; nominations declared closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortrea
- Raised 2026 guidance after strong Q2 execution, improved profitability, and robust backlog.FTRE
Q2 2026 - Strong book-to-bill, commercial transformation, and debt reduction highlight strategic progress.FTRE
Jefferies 2024 Global Healthcare Conference - Demand, bookings, and technology integration are driving recovery and positioning for future growth.FTRE
Jefferies Global Healthcare Conference 2026 - Adjusted EBITDA rose to $47M as net loss narrowed and guidance was reaffirmed.FTRE
Q1 2026 - Annual meeting covers director elections, auditor ratification, and executive pay, with strong governance focus.FTRE
Proxy filing - Votes will be held on director elections, auditor ratification, and executive pay approval.FTRE
Proxy filing - 2025 results met guidance; 2026 targets margin growth and stability despite goodwill impairment.FTRE
Q4 2025 - Driving clinical trial modernization and margin expansion in a $40B global market.FTRE
44th Annual J.P. Morgan Healthcare Conference - Q3 revenue up 3.9%, net loss narrowed, but goodwill impairment led to a large YTD loss.FTRE
Q3 2025